Joseph E. Gilliam serves as the President and Chief Operating Officer at Glaukos Corporation, a leading ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. In his role, Gilliam is responsible for overseeing the company's global operations, including sales, marketing, and research and development, ensuring that Glaukos continues to innovate and deliver high-quality products to its customers worldwide. Gilliam brings a wealth of experience to his position, having spent over two decades in the medical device and pharmaceutical industries. Prior to joining Glaukos, he held various leadership positions at companies such as Abbott Laboratories and Allergan, where he demonstrated a proven track record of driving growth and operational excellence. His strategic vision and deep understanding of the healthcare sector have been instrumental in guiding Glaukos through its expansion and diversification efforts, particularly in the development of its pipeline of innovative products. Under Gilliam's leadership, Glaukos has achieved significant milestones, including the successful launch of several new products and the expansion of its global footprint. His commitment to fostering a culture of innovation and collaboration has been key to the company's success, as evidenced by its strong financial performance and growing market share. As President and COO, Gilliam continues to play a pivotal role in shaping the future of Glaukos, ensuring that the company remains at the forefront of the ophthalmic industry.